Valeant Pharmaceuticals Intl Inc (NYSE:VRX) in a number of its board meetings has had the matter about a name change delved into in a great way. This is still on the weighing balance and eyes are wide open to see what actually happens.
The company’s chief executive Joseph Papa while making a statement outlined that the company has lately been looking into the various alternatives that it has. In an annual meeting held in Laval, Que came as a major eye opener to a lot of the provider’s investors.
A number of top news reporters made efforts to reach out and get the top company executive to make remarks on whether or not they were to expect the name change within a short time frame. They also needed to know what the exact name was to be.
However, their efforts were all in vain considering that the top official had declined to make any comments, for reasons better known to him. This at that point in time sparked a lot of uncertainties among the various investors as well as the concerned parties. Eyebrows remain raised as the company continues with its internal operations in a move to try and keep up with the competition the world markets.
When confronted at a different place and a different time, there was not quite much that could be gotten from the top official. He had shortly moved ahead to make a comment saying, “There is an effort under way to look at that. And as soon as we’re ready, we’ll be out there with specifics on that. But it is something that we’ve taken very seriously as we’ve thought about the company, the perception.”
Let’s face it; as a matter of fact Papa’s track record is unbeatable. However, the recent months in the company are bringing to the table different realities. They have been quite challenging times and according to a number of top trusted sources, the company will most probably experience an eventual fall in earnings as well as sales. That will of course come as a great disappointment to most of those that invest with the provider.